Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript
· seekingalpha.com
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder August 12, 2026 8:00 AM...
Presentation
Hello, and welcome to the Definium Therapeutics Phase III Voyage Topline Results Call. [Operator Instructions] As a reminder, this conference is b...